Ivoclar Vivadent Inc. · Mar 13 - 14 · Sarasota, FL
Ivoclar Vivadent Inc. · Mar 17 - 18 · Troy, MI
Ivoclar Vivadent Inc. · Apr 28 - 29 · Troy, MI
Ivoclar Vivadent Inc. · May 5 - 6 · Canoga Park, CA
Find Everything Software on The BRIDGE!
The BRIDGE is an online network from LMT dedicated exclusively for members of the Dental Laboratory community. Join free to learn more about Software and other topics.
National Dentex Corporation (“NDX”) announces the acquisition of nSequence Center for Advanced Dentistry (“nSequence”) based in Reno, NV. nSequence (www.nsequence.com) is a state...See more of the art full service digital and conventional dental laboratory that specializes in CT guided surgery and guided prosthetics. nSequence was founded and operated by Daniel Llop, CDT. “We are excited to have nSequence join NDX. nSequence uses technology to take into account treatment techniques, implant systems, physiology of the patient, and aesthetics when planning a case. Innovation at nSequence has been driven by Daniel Llop, CDT who understands the goals of the surgical and restorative team, as well as the capabilities of an experienced dental technician, and the awesome potential of technology in virtual case planning,” commented Steven Casper, NDX Chief Executive Officer. nSequence brings to the market broad surgical and prosthetic guidance capability. While they can accept treatment plans for all guided surgery systems and software on the market today, they have also developed their own FDA 510k cleared proprietary system called Maven Pro. Maven Pro is a comprehensive implant and prosthetic planning software that can display surgical and restorative options and allows for live web collaboration between the physician, the dental technician, and in some circumstances the patient, before gaining case acceptance and determining the case plan. “In the exciting field of pre-operative virtual guided surgery and prosthetic planning I realized an opportunity to increase insight and understanding of a patient’s anatomy, surgical and prosthetic options and approaches before a scalpel or drill was used. The creation of the virtual patient has taken the dental professional to a new level of communication with their peers and patients. With fewer office visits, chair time, increased accuracy and lower costs associated with the treatment, the patient has clearly been the main benefactor. I am so pleased that NDX shares our vision of the future of CT guided surgery and the expanding role of the dental lab and the technician,” commented Daniel Llop. Daniel Llop will continue to run day to day operations at nSequence and joins the NDX leadership team as the Director of CT Guided Implant Technology.
EPS up 13.5% to $1.43 Henry Schein, Inc., the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners, today reported record financial...See more results for the quarter ended December 28, 2013. Net sales for the fourth quarter of 2013 were $2.5 billion, an increase of 4.9% compared with the fourth quarter of 2012. This consisted of 4.4% growth in local currencies and 0.5% growth related to foreign currency exchange. In local currencies, internally generated sales increased 3.7% and acquisition growth was 0.7% (see Exhibit A for details of sales growth). Net income attributable to Henry Schein, Inc. for the fourth quarter of 2013 was $124.3 million or $1.43 per diluted share, an increase of 10.5% and 13.5%, respectively, compared with the fourth quarter of 2012. "We are pleased to complete a very successful 2013 with strong fourth quarter results," said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein. "Sales growth during the fourth quarter was solid and on plan. Importantly, we believe we gained market share in each of our four global business units and exceeded the top of our original EPS guidance range for the year." Global Dental sales of $1.4 billion increased 3.9%, consisting of 3.1% growth in local currencies and 0.8% growth related to foreign currency exchange. In local currencies, internally generated sales increased 2.6% and acquisition growth was 0.5%. The 2.6% internal growth in local currencies included 2.1% growth in North America and 3.5% growth in International. "Gains in North America Dental sales included solid growth in consumable merchandise, while equipment sales and service revenue declined slightly following growth of nearly 22% in the prior-year quarter, making for a challenging comparison," commented Mr. Bergman. "International Dental returned to growth during the quarter as consumable merchandise posted positive gains and equipment sales and service revenue growth accelerated from the previous quarter." Global Animal Health sales of $651.7 million increased 6.6%; there was no material impact on sales growth from foreign currency exchange. Internally generated sales increased 4.8% and acquisition growth was 1.8%. The 4.8% internal growth in local currencies included 7.0% growth in North America and 2.9% growth in International. "Once again our Global Animal Health business performed well during the quarter. North America internal sales growth in the high single digits is consistent with our stated goals, and International Animal Health internal sales growth in local currencies accelerated slightly versus the prior quarter," commented Mr. Bergman. Global Medical sales of $421.9 million increased 4.8%, including 4.6% growth in local currencies and 0.2% growth related to foreign currency exchange. "Reported Global Medical growth benefitted from higher sales of seasonal influenza vaccines versus the prior year. Excluding this impact, our Global Medical sales growth accelerated slightly compared to the third quarter. We believe patient traffic to U.S. physician offices was largely consistent with the prior quarter," remarked Mr. Bergman. "We are confident that our focus on large group practices will allow us to continue to gain market share." Global Technology and Value-Added Services sales of $88.4 million increased 8.6%, including 8.9% growth in local currencies and a 0.3% decline related to foreign currency exchange. In local currencies, internally generated sales increased 8.6% and acquisition growth was 0.3%. "Technology and Value-Added Services growth was driven by electronic services recurring revenue, software sales and value-added services," commented Mr. Bergman. "Sales in International markets were particularly strong." Stock Repurchase Plan The Company announced that it repurchased approximately 664,000 shares of its common stock during the fourth quarter at an average price of $111.04 per share, or approximately $73.8 million. The impact of the repurchase of shares on fourth quarter diluted EPS was immaterial. For the full year 2013 the Company repurchased $300.3 million in stock, representing 3.1 million shares at an average price of $97.71 per share, which is in line with our stated goals. At the close of the fourth quarter, Henry Schein had approximately $300 million authorized for future repurchases of its common stock. Full-Year Results For 2013, net sales of $9.6 billion increased 6.9% compared with 2012. This consisted of 6.8% growth in local currencies and 0.1% growth related to foreign currency exchange. In local currencies, internally generated sales increased 3.6% and acquisition growth was 3.2%. Net income attributable to Henry Schein, Inc. for 2013 was $431.6 million or $4.93 per diluted share. Excluding certain one-time items, adjusted net income attributable to Henry Schein, Inc. for 2013 was $433.4 million or $4.95 per diluted share, an increase of 8.7% and 11.5%, respectively, compared with adjusted net income for 2012 (see Exhibit B for reconciliation of GAAP net income and EPS to non-GAAP adjusted net income and EPS). 2014 EPS Guidance Henry Schein today affirmed 2014 financial guidance, as follows: For 2014 the Company expects diluted EPS attributable to Henry Schein, Inc. to be $5.29 to $5.39, which represents growth of 7% to 9% compared with 2013 results excluding certain one-time items. The Company expects that growth in diluted EPS for 2014 will accelerate over the course of the year, due to a number of timing factors including the impact of recent acquisitions. Guidance for 2014 diluted EPS attributable to Henry Schein, Inc. is for current continuing operations as well as completed or previously announced acquisitions, and does not include the impact of potential future acquisitions, if any. Fourth Quarter Conference Call Webcast The Company will hold a conference call to discuss fourth quarter financial results today, beginning at 10:00 a.m. Eastern time. Individual investors are invited to listen to the conference call over the Internet through Henry Schein's website at www.henryschein.com. In addition, a replay will be available beginning shortly after the call has ended.
Zahn Dental, the Laboratory Division of Henry Schein, Inc., was recently named the preferred laboratory consumables partner for OPT-In Laboratory Cooperative by OPT-In Management, LLC. Zahn Dental...See more joins BEGO USA, Dental Wings and LabStar Software (formerly, Soundtrack) as a key corporate member in OPT-In’s strategic growth. “Working with OPT-In Dental Laboratory Cooperative helps us more effectively reach a market that has always been important to us,” said Rita Acquafredda, General Manager and Vice President, Zahn Dental. “With this partnership, we can more easily provide business support that will help small laboratories operating under the OPT-In brand become more profitable. We are thrilled to be working in support of OPT-In and to hold a strategic position amongst their current list of corporate partners.” As a strategic partner, Zahn will provide consumables and business support to laboratories operating under the OPT-In Brand. “Zahn’s position within our corporate partner network brings us closer to completing the OPT-In vision of an industry working together to serve the common good.” said Dr. Dean Mersky, President, OPT-In Management, LLC.
Shareholders in Delcam, one of the world’s leading suppliers of advanced software for manufacturing industry, today voted to accept the offer made by Autodesk to acquire the company. The acquisition...See more is expected to be completed during February. Headquartered in Birmingham, UK, Delcam has more than 30 offices worldwide and over 700 employees. The company’s range of design, manufacturing and inspection software provides automated CAD/CAM solutions for a variety of industries, ranging from automotive and aerospace to footwear and healthcare. The latest NC Software Market Analysis Report from leading US analysts CIMdata showed that, in 2012, Delcam again had the highest vendor revenues and received the highest end-user payments of all the CAM-centric companies. This result meant that the company completed thirteen years as the world’s leading specialist supplier of CAM software and services. Autodesk and Delcam offer complementary ranges of software, with Autodesk’s programs for design, engineering and entertainment able to be combined with Delcam strengths in manufacturing. On completion of the acquisition, Delcam will become a subsidiary of Autodesk. It will maintain its focus on accelerating the growth of its market share in the manufacturing sector, with the added strength that will come from being part of a larger organisation. Delcam customers will continue to be supported by the skilled and experienced engineers for which the company is renowned through its global network of Subsidiaries, Joint Ventures and Sales Partners.
The 22nd annual meeting of the European Association of Osseointegration (EAO), October 17-19, 2013, served as the platform for Nobel Biocare to launch several new innovative solutions, each focused on...See more improving patient treatment outcomes while increasing efficiency for both clinicians and laboratories. At the Convention Center Dublin, Ireland, Nobel Biocare showcased products and services which further highlight the company's commitment to leading innovation. All of the solutions presented will play important roles in Nobel Biocare's upcoming new seamless and fully integrated digital treatment workflow. New NobelProcera® 2G System gives laboratories the opportunity to build their business Reducing the time required for scanning by up to 50%, and with no compromise on precision, the new NobelProcera 2G System now offers dental labs multiple benefits at a level that can help them to grow their business. From single teeth to complex edentulous cases, the NobelProcera 2G System's increased automation capabilities and simplified workflows reduce the need for user interaction to a bare minimum, allowing dental technicians to focus on other tasks while scanning takes place, increasing the productivity of the lab. The NobelProcera 2G System can also now help labs to become more valued treatment partners. The new 2G scanner's solid model scanning capability allows for the production of highly precise digitized model surface information. This can inform the clinician's diagnostic process, involving the lab at an early stage in the treatment program, providing the opportunity to discuss restorative options for an optimum esthetic outcome. Nobel Biocare is running an exchange program which makes it easy to upgrade to the NobelProcera 2G System. Interested customers should contact their local Nobel Biocare representative today. New 'open access' gives 3Shape® customers the outstanding quality of NobelProcera® Abutments The industry-leading customized abutments from NobelProcera are now available for users of the 3Shape Dental System. After integrating with NobelProcera, 3Shape users can access the extensive global production network of NobelProcera to produce high-quality NobelProcera Abutments in zirconia and titanium for both Nobel Biocare and other major implant systems. Interested 3Shape users should contact their local Nobel Biocare representative. Availability may depend on the version in use and which 3Shape Partner has provided the Dental System. Learn more about the NobelProcera 2G System and open access at: nobelbiocare.com/nobelprocera Fully integrated digital workflow moves a step closer with NobelClinician™ Software and OsseoCare™ Pro iPad®-powered drill unit now connected The digital link that has now been established between the NobelClinician Software and the iPad-powered OsseoCare Pro drill unit will support optimal patient treatment, treatment file management and greater efficiency. Thanks to the new connection, users of the NobelClinician Software can now digitally transfer a surgery planned in NobelClinician to the intelligent OsseoCare Pro drill unit via Nobel Biocare's cloud-based network NobelConnect. The chosen implants in the correct positions and with the required drilling protocol are transferred to the OsseoCare Pro drill unit at little more than the press of a button. A patient-specific post-surgery report is now also sent straight from the OsseoCare Pro back to NobelClinician once the procedure is complete, significantly increasing the efficiency of implant placement. This new connection is an important link within Nobel Biocare's fully integrated digital treatment workflow which will become fully connected in 2014. Once in place, the full digital workflow will significantly increase predictability, efficiency and the quality of patient care at every step of the treatment process. Learn more about NobelClinician Software and OsseoCare Pro at: nobelbiocare.com/nobelclinician or nobelbiocare.com/osseocare
Bob Cohen, CDT · June 6, 2012
Hi, Being a reseller of CAD CAM equipment we have found it to be very interesting that many decision makers in dental labs want help figuring out if it's the right time to buy. From a business perspective...See more it's all about return on investment (ROI). So, for the sake of this exercise let's look at the cost of borrowing $10K over 5 years. Based on 21 manufacturing days in a month the $10K turns out to cost about $8.50 per day. So, a $27K scanner will run a little less than $25 per day. That said, if you are outsourcing models and the model base work flow is costing $25 more than just sending a digital file for manufacturing you can logically see that it does not take much work to get to a break even or to become significantly more profitable. In addition, you need to add in the labor to scan and design the cases in your facility. This cost can very widely with efficiency of the individual(s) performing this operation. On the other side of the coin, you gain the savings of the cost of packaging and shipping (in addition to time savings). In reality, these two costs may be close to equal, so, it's a wash. In conclusion, labs outsourcing 20 plus units a month are at the break even point to purchase a scanner and CAD software that is in the cost range of about $27K. In conclusion, one can figure a daily cost of about $8.50 per $10K borrower over 5 years. Hope this post can help some of those in question. Please feel free to add comments. Bob
Laura Sheppard · May 18, 2012
The NBC has been asked for CAD CAM credentialling. I know it sounds good on paper. But practically, how would you envision a CAD CAM test to be, that would credential this skill set? What would we test...See more candidates on (designing?), how would we evaluate it and what tools would be required? Keeping in mind that each test facility would likely need to have the process(s) on site? Or, would each candidate bring a lap top with software? would there be a production element? Also, the industry does not have one universal open-architect system that all candidates would have access to, or be trained on. And, non-vendor specific training materials need to be available......any and all ideas are welcome. :)
In the early 1980s, industry forecasters predicted a boon in implant placement, a prediction that was premature for a market still in its infancy. Inadequate education, inconsistent techniques and unpredictable...See more results contributed to resistance on the part of many dentists and laboratories. However, by the time we entered the new millennium, implant treatment became the first choice in tooth replacement thanks to technical advancements, long-term success rates, and the abundance of manufacturer-provided education. The advent of CAD/CAM and cone beam technology further impacted the precision of implant placement with the development of sophisticated treatment planning software and surgical guides, making surgery more straightforward for the doctor and less traumatic for the patient. As of 2013, laboratories reported that two-thirds of their dentist-clients were prescribing implant restorations, according to LMT’s Implant Survey. Visit LMTmag.com tomorrow for another LMT Memorable Moment.
Computer systems across the globe were at risk of failing after midnight, December 31, 1999 thanks to the “Millennium Bug.” For decades prior to 2000, computer software had been designed with...See more a two-digit year code—“98” for 1998, for example—and the fear was that when computers’ internal clocks changed to “00” the computers wouldn’t be able to tell the difference between the year 2000 and the year 1900. Like business owners everywhere, some laboratory owners were concerned by what the “mother of all computer glitches,” would mean not only for their computer systems, but also embedded systems in things like furnaces, telephones and alarm systems. Even if they were safe, would there be glitches at their banks, suppliers or clients’ offices? In the end—on January 1—the much-hyped pandemonium never happened and no major failures were ever reported. Visit LMTmag.com tomorrow for another LMT Memorable Moment.
LMT Publisher Judy Fishman talks with Tim Thompson, President and CEO of Global Dental Science, LLC in Phoenix AZ about the AvaDent Digital Dentures system.